18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

53 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-22

Study Completion Date

2021-10-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

18F-GP1 binds with high affinity to the glycoprotein IIb/IIIa receptors on activated platelets. 18F-GP1 PET-CT has recently demonstrated favourable safety, pharmacokinetic, biodistribution and diagnostic performance for the in vivo identification of venous and arterial thrombemboli.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer

NCT03943966

Thrombosis Atherothrombosis Myocardial Infarction +8 more

COMPLETED NA

PET-MR Imaging of Coronary Atherothrombosis

NCT03618303

Heart Diseases, Ischemic

COMPLETED NA

Positron Emission Tomography (PET) Imaging of Thrombosis

NCT03830320

Atrial Fibrillation COVID-19 Cancer +1 more

RECRUITING PHASE1

Development and Validation of a Fast, Semi-Automated Hybrid Imaging Platform to Assess Coronary Atherosclerotic Plaque Morphology, Endothelial Shear Stress and Arterial Inflammation: A Proof of Principle Study (VALID-PET-CT)

NCT04205110

Stable Angina Coronary Artery Disease

COMPLETED

18F Sodium Fluoride PET/CT in Acute Aortic Syndrome

NCT03647566

Acute Aortic Syndrome Aortic Dissection Penetrating Aortic Ulcer +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aortic stenosis is the most common reason for valvular interventions in the developed world, with rates projected to increase as the population ages. Aortic valve replacement remains the only recognised treatment available. Bioprostheses are far more common than mechanical prostheses, particularly with increasing rates of transcatheter heart valve use.

Bioprothetic valves are less durable than mechanical valves and are subject to deterioration which may lead to clinical heart failure and the need for re-intervention. Long-term results with surgical bioprostheses are well reported, with valve deterioration rates of less than 15% at 10 years. These data, however, rely on re-operation rather than echocardiographic measures, suggesting that the true incidence of structural valve deterioration is underestimated.

Valve thrombosis is increasingly recognised as a potential contributor to leaflet degeneration and has been detected in participants undergoing both surgical aortic valve replacement and transcatheter aortic valve implantation. The role of valve thrombosis as an early trigger for calcification and subsequent valve degeneration has not been addressed. The true incidence of valve thrombosis and its impact on clinical outcomes is unknown due to the lack of a sufficiently sensitive non-invasive imaging modality to detect early subclinical thrombosis. Current observational data suggests rates of 12 to 40%, based on computed tomography findings. There is a clinical need for a more sensitive non-invasive method of detecting valve thrombosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombosis Cardiac Aortic Valve Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bioprosthetic aortic valve

Single 18F-GP1 PET-CT

18F-GP1

Intervention Type DIAGNOSTIC_TEST

18F-GP1 PET-CT scan

Bioprosthetic aortic valve thrombus - repeat imaging

18F-GP1 PET-CT at baseline and 3 months

18F-GP1

Intervention Type DIAGNOSTIC_TEST

18F-GP1 PET-CT scan

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18F-GP1

18F-GP1 PET-CT scan

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ability to give informed consent
* \>1 month post-surgical or transcatheter aortic valve replacement

Exclusion Criteria

* Inability to give informed consent
* Pregnancy or breastfeeding
* Contraindications to iodinated contrast
* Contraindications to anticoagulation
* Use of anticoagulants during the post-operative period prior to screening
* Extreme claustrophobia
* Chronic kidney disease (with estimated glomerular filtration rate \<30 mL/min/1.73m2)
* Metastatic malignancy
* Inability to tolerate the supine position

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No